This atypical serine/threonine kinase, involved in the phosphoinositide 3-kinase (PI3K)/Akt pathway and participating in two protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), is a well-known target for cancer therapy. This evidence concerns the gene MARK2 and cancer.